Literature DB >> 22122637

Cancer stem cell epigenetics and chemoresistance.

Francesco Crea1, Romano Danesi, William L Farrar.   

Abstract

Cancer stem cells (CSCs) are thought to sustain cancer progression, metastasis and recurrence after therapy. There is in vitro and in vivo evidence supporting the idea that CSCs are highly chemoresistant. Epigenetic gene regulation is crucial for both stem cell biology and chemoresistance. In this review, we summarize current data on epigenetic mechanisms of chemoresistance in cancer stem cells. We propose a model integrating classical CSC pathways (Wnt, Hedgehog and Notch), epigenetic effectors (Polycomb) and drug resistance genes (ABCG2, CD44). Moreover, we analyze the potential of epigenetic drugs to reverse CSC chemoresistance. In the future, CSC epigenomic profiling could help to dissect specific chemoresistance pathways, and have a significant clinical impact for patient stratification and rational design of therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 22122637     DOI: 10.2217/epi.09.4

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  30 in total

1.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

Review 2.  Diverse involvement of EZH2 in cancer epigenetics.

Authors:  Pamela Völkel; Barbara Dupret; Xuefen Le Bourhis; Pierre-Olivier Angrand
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

3.  Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.

Authors:  Qinlong Li; Quanlin Li; Jill Nuccio; Chunyan Liu; Peng Duan; Ruoxiang Wang; Lawrence W Jones; Leland W K Chung; Haiyen E Zhau
Journal:  Prostate       Date:  2015-05-19       Impact factor: 4.104

Review 4.  Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.

Authors:  Alex J Gooding; William P Schiemann
Journal:  Mol Cancer Res       Date:  2020-06-05       Impact factor: 5.852

Review 5.  AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.

Authors:  Bowen Yan; David Claxton; Suming Huang; Yi Qiu
Journal:  Exp Hematol       Date:  2020-06-20       Impact factor: 3.084

6.  Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells.

Authors:  Yu Yang; Jiajie Hou; Zhe Lin; Han Zhuo; Dianyu Chen; Xudong Zhang; Yun Chen; Beicheng Sun
Journal:  Cell Mol Immunol       Date:  2014-02-03       Impact factor: 11.530

7.  BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.

Authors:  Francesco Crea; Maria A Duhagon Serrat; Elaine M Hurt; Suneetha B Thomas; Romano Danesi; William L Farrar
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

8.  G9a/RelB regulates self-renewal and function of colon-cancer-initiating cells by silencing Let-7b and activating the K-RAS/β-catenin pathway.

Authors:  Shih-Ting Cha; Ching-Ting Tan; Cheng-Chi Chang; Chia-Yu Chu; Wei-Jiunn Lee; Been-Zen Lin; Ming-Tsan Lin; Min-Liang Kuo
Journal:  Nat Cell Biol       Date:  2016-08-15       Impact factor: 28.824

9.  Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.

Authors:  Dong-Rong Yang; Xian-Fan Ding; Jie Luo; Yu-Xi Shan; Ronghao Wang; Shin-Jen Lin; Gonghui Li; Chiung-Kuei Huang; Jin Zhu; Yuhchyau Chen; Soo Ok Lee; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

10.  Histone lysine demethylases in breast cancer.

Authors:  Elisa Paolicchi; Francesco Crea; William L Farrar; Jeffrey E Green; Romano Danesi
Journal:  Crit Rev Oncol Hematol       Date:  2012-12-23       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.